Thyrocare Technologies Limited announced that the Board of Directors of the Company held its meeting on, May 07, 2026. The Board took note of the resignation of Mr. Dharmil Nirupam Sheth, Non-Executive, Non-Independent Director of the Company, who has tendered his resignation due to pre-occupation and other commitments, with effect from the close of business hours on May 07, 2026. Consequent to his resignation, he shall also cease to be a member of the following Committees of the Board: Nomination and Remuneration Committee, Stakeholders' Relationship Committee, Risk Management Committee.
The Board took note of the resignation of Dr. Dhaval Rajesh Shah, Non-Executive, Non- Independent Director of the Company, who has tendered his resignation due to pre-occupation and other commitments, with effect from the close of business hours on May 07, 2026. The Company has also received confirmation from Dr. Dhaval Rajesh Shah that there are no material reasons for his resignation other than those stated in his resignation letter dated April 30, 2026. Consequent to his resignation, he shall also cease to be a member of the Corporate Social Responsibility Committee of the Board.
Thyrocare Technologies Limited is an India-based company, which operates as a healthcare services provider. It offers a range of diagnostic and related healthcare tests and services that are focused on early detection, preventive care, and ongoing disease monitoring. Its segments include diagnostic testing services, Imaging Services, and others. The Diagnostic Testing Services segment includes diagnostic and testing services, selling of consumables used for collection and promotion of pathology. The Imaging Services include diagnostic and imaging services, the selling of radiopharmaceuticals, and consumables for reporting. The Others segment includes the sale of testing equipment and consumables, and the selling of glucometer and glucostrips under the brand, Sugarscan. It has a centralized fully automated diagnostic testing laboratory, regional processing laboratories, and a medical cyclotron facility across India. It is also focused on offering pathological services.
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
-
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
-
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
-
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
